Edition:
United Kingdom

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

27.06USD
15 Dec 2017
Change (% chg)

$0.43 (+1.61%)
Prev Close
$26.63
Open
$26.67
Day's High
$27.32
Day's Low
$25.65
Volume
417,220
Avg. Vol
130,183
52-wk High
$38.75
52-wk Low
$21.39

Latest Key Developments (Source: Significant Developments)

Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis.Dermira Inc - ‍FDA decision on new drug application for glycopyrronium tosylate expected by June 30, 2018​.Dermira Inc - qtrly net loss per share, basic and diluted $4.30 ‍​.Dermira Inc - updating its financial guidance for full year 2017; now expects collaboration and license revenue of approximately $4.3 million for FY​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article

Dermira reports Q2 loss per share $0.89
Monday, 8 Aug 2016 

Dermira Inc : Dermira reports second quarter 2016 financial results and provides corporate update . Says continues to estimate GAAP operating expenses of $110-120 million for 2016 . Dermira Inc qtrly loss per share $0.89 .Says now expects GAAP operating expenses to be at upper end of range of $110-120 million for 2016.  Full Article

Dermira public offering of 4.50 mln common shares priced at $28 per share
Wednesday, 8 Jun 2016 

Dermira Inc : Says public offering of 4.50 million common shares priced at $28.00per share .Dermira prices $126 million public offering of common stock.  Full Article

Dermira announces proposed public offering of common stock
Tuesday, 7 Jun 2016 

Dermira: Dermira announces proposed public offering of common stock .Also expects to grant to underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of shares sold in offering.  Full Article

Dermira reports Q1 net loss per share $0.95
Tuesday, 10 May 2016 

Dermira Inc : Dermira reports first quarter 2016 financial results and provides corporate update . Announcement of topline results for drm04 phase 3 hyperhidrosis pivotal trials expected in Q2 of 2016 .Qtrly net loss per share $0.95.  Full Article

Dermira announces positive phase 2B trial results for DRM01
Tuesday, 10 May 2016 

Dermira Inc : Clinical study evaluated safety and efficacy of DRM01 and demonstrated statistically significant improvements in all primary endpoints . Plans to initiate a phase 3 program to evaluate safety and efficacy of drm01 as a treatment for acne in adult and adolescent patients . Initiation of program is targeted for first half of 2017, subject to an end-of-phase 2 meeting with fda .Dermira announces positive topline phase 2b clinical trial results for drm01 in patients with facial acne vulgaris.  Full Article

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis